CA2847286A1 - Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete - Google Patents

Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete Download PDF

Info

Publication number: CA2847286A1
Authority: CA; Canada
Prior art keywords: borapetoside; mice; subject; insulin; diabetes
Prior art date: 2014-03-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2847286A

Other languages

English (en)

Inventor

Ming-Jai Su

Shoei-Sheng Lee

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ORIENT EUROPHARMA CO Ltd

Original Assignee

ORIENT EUROPHARMA CO Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-20

Filing date

2014-03-20

Publication date

2015-09-20

2014-03-20 Application filed by ORIENT EUROPHARMA CO Ltd filed Critical ORIENT EUROPHARMA CO Ltd

2014-03-20 Priority to CA2847286A priority Critical patent/CA2847286A1/fr

2015-09-20 Publication of CA2847286A1 publication Critical patent/CA2847286A1/fr

Status Abandoned legal-status Critical Current

Links

206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 73
239000000203 mixture Substances 0.000 title abstract description 63
238000002560 therapeutic procedure Methods 0.000 title abstract description 4
-1 diterpenoid compounds Chemical class 0.000 title description 23
GCXIISSOWSXMCD-WOVZMQRJSA-N borapetoside A Natural products C[C@]12C[C@H](OC(=O)[C@@H]1C[C@@H]3OC(=O)[C@@]4(O)[C@@H](CC[C@H]2[C@]34C)O[C@H]5O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]5O)c6cocc6 GCXIISSOWSXMCD-WOVZMQRJSA-N 0.000 claims abstract description 134
GCXIISSOWSXMCD-MZYRCUENSA-N borapetoside a Chemical compound O([C@H]1CC[C@H]2[C@]3(C)C[C@H](OC(=O)[C@@H]3C[C@H]3[C@]2([C@@]1(O)C(=O)O3)C)C1=COC=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCXIISSOWSXMCD-MZYRCUENSA-N 0.000 claims abstract description 134
150000003839 salts Chemical class 0.000 claims abstract description 19
239000002207 metabolite Substances 0.000 claims abstract description 16
239000000651 prodrug Substances 0.000 claims abstract description 12
229940002612 prodrug Drugs 0.000 claims abstract description 12
239000012453 solvate Substances 0.000 claims abstract description 12
206010022491 Insulin resistant diabetes Diseases 0.000 claims abstract description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 40
239000008103 glucose Substances 0.000 claims description 37
238000000034 method Methods 0.000 claims description 36
229920002527 Glycogen Polymers 0.000 claims description 35
229940096919 glycogen Drugs 0.000 claims description 35
210000004185 liver Anatomy 0.000 claims description 28
108090001005 Interleukin-6 Proteins 0.000 claims description 22
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 22
102100040257 TBC1 domain family member 4 Human genes 0.000 claims description 12
101710107476 TBC1 domain family member 4 Proteins 0.000 claims description 12
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
230000007423 decrease Effects 0.000 claims description 8
230000026731 phosphorylation Effects 0.000 claims description 8
238000006366 phosphorylation reaction Methods 0.000 claims description 8
230000004968 inflammatory condition Effects 0.000 claims description 6
230000003914 insulin secretion Effects 0.000 claims description 6
108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 claims 2
102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 claims 2
206010061218 Inflammation Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 108
241000699670 Mus sp. Species 0.000 description 94
150000001875 compounds Chemical class 0.000 description 94
102000004877 Insulin Human genes 0.000 description 54
108090001061 Insulin Proteins 0.000 description 54
229940125396 insulin Drugs 0.000 description 54
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 37
239000008194 pharmaceutical composition Substances 0.000 description 36
238000011282 treatment Methods 0.000 description 33
238000009472 formulation Methods 0.000 description 30
239000000243 solution Substances 0.000 description 26
239000003981 vehicle Substances 0.000 description 26
210000004027 cell Anatomy 0.000 description 25
102000004889 Interleukin-6 Human genes 0.000 description 21
229940100601 interleukin-6 Drugs 0.000 description 21
241001465754 Metazoa Species 0.000 description 19
230000000694 effects Effects 0.000 description 18
235000002639 sodium chloride Nutrition 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
239000007924 injection Substances 0.000 description 16
238000002347 injection Methods 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 15
201000010099 disease Diseases 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
239000003814 drug Substances 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 14
239000000725 suspension Substances 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 13
102000003746 Insulin Receptor Human genes 0.000 description 12
108010001127 Insulin Receptor Proteins 0.000 description 12
239000004480 active ingredient Substances 0.000 description 12
229940090044 injection Drugs 0.000 description 12
229960003105 metformin Drugs 0.000 description 12
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
239000008280 blood Substances 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000000969 carrier Substances 0.000 description 11
230000003247 decreasing effect Effects 0.000 description 11
239000007788 liquid Substances 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
210000002027 skeletal muscle Anatomy 0.000 description 11
239000003381 stabilizer Substances 0.000 description 11
239000002552 dosage form Substances 0.000 description 10
239000000499 gel Substances 0.000 description 10
239000000126 substance Substances 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
239000000443 aerosol Substances 0.000 description 9
239000002775 capsule Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
108091006299 SLC2A2 Proteins 0.000 description 8
102100023537 Solute carrier family 2, facilitated glucose transporter member 2 Human genes 0.000 description 8
229940079593 drug Drugs 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000003755 preservative agent Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
206010022489 Insulin Resistance Diseases 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
210000003494 hepatocyte Anatomy 0.000 description 7
235000000346 sugar Nutrition 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000002270 dispersing agent Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
230000002708 enhancing effect Effects 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
230000002218 hypoglycaemic effect Effects 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
239000002502 liposome Substances 0.000 description 5
210000005228 liver tissue Anatomy 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000003826 tablet Substances 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
108091008611 Protein Kinase B Proteins 0.000 description 4
238000010171 animal model Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000002585 base Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
230000002440 hepatic effect Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
238000001262 western blot Methods 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108091052347 Glucose transporter family Proteins 0.000 description 3
102000042092 Glucose transporter family Human genes 0.000 description 3
206010020710 Hyperphagia Diseases 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
108091007960 PI3Ks Proteins 0.000 description 3
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
208000004880 Polyuria Diseases 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
240000003428 Tinospora crispa Species 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
230000023852 carbohydrate metabolic process Effects 0.000 description 3
235000021256 carbohydrate metabolism Nutrition 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000008298 dragée Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000945 filler Substances 0.000 description 3
230000010030 glucose lowering effect Effects 0.000 description 3
230000004190 glucose uptake Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
238000012545 processing Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000011664 signaling Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000037317 transdermal delivery Effects 0.000 description 3
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
239000004338 Dichlorodifluoromethane Substances 0.000 description 2
241000792859 Enema Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010043458 Thirst Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
102000002689 Toll-like receptor Human genes 0.000 description 2
108020000411 Toll-like receptor Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229960004424 carbon dioxide Drugs 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
229940042935 dichlorodifluoromethane Drugs 0.000 description 2
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 2
OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000007920 enema Substances 0.000 description 2
229940079360 enema for constipation Drugs 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
230000004110 gluconeogenesis Effects 0.000 description 2
238000007446 glucose tolerance test Methods 0.000 description 2
230000006377 glucose transport Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
235000003642 hunger Nutrition 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000027939 micturition Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
102000007863 pattern recognition receptors Human genes 0.000 description 2
108010089193 pattern recognition receptors Proteins 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
206010036067 polydipsia Diseases 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
208000022530 polyphagia Diseases 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000002363 skeletal muscle cell Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
235000011121 sodium hydroxide Nutrition 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
229940029284 trichlorofluoromethane Drugs 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000009736 wetting Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
238000009020 BCA Protein Assay Kit Methods 0.000 description 1
238000000035 BCA protein assay Methods 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
239000004155 Chlorine dioxide Substances 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102000016354 Glucuronosyltransferase Human genes 0.000 description 1
108010092364 Glucuronosyltransferase Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
102000005237 Isophane Insulin Human genes 0.000 description 1
108010081368 Isophane Insulin Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
241000218164 Menispermaceae Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101150045799 PEPCK gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091006300 SLC2A4 Proteins 0.000 description 1
108010026951 Short-Acting Insulin Proteins 0.000 description 1
229940123958 Short-acting insulin Drugs 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
230000008777 canonical pathway Effects 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000002038 chemiluminescence detection Methods 0.000 description 1
235000019398 chlorine dioxide Nutrition 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229940093181 glucose injection Drugs 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
229940025770 heparinoids Drugs 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
238000012528 insulin ELISA Methods 0.000 description 1
230000004155 insulin signaling pathway Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
208000020442 loss of weight Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
229940105902 mint extract Drugs 0.000 description 1
239000003595 mist Substances 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
229920004905 octoxynol-10 Polymers 0.000 description 1
229920004914 octoxynol-40 Polymers 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
229940043138 pentosan polysulfate Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229930029653 phosphoenolpyruvate Natural products 0.000 description 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
231100000064 subacute toxicity study Toxicity 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
239000012443 tonicity enhancing agent Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000001993 wax Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2847286A 2014-03-20 2014-03-20 Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete Abandoned CA2847286A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2847286A CA2847286A1 (fr)	2014-03-20	2014-03-20	Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2847286A CA2847286A1 (fr)	2014-03-20	2014-03-20	Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete

Publications (1)

Publication Number	Publication Date
CA2847286A1 true CA2847286A1 (fr)	2015-09-20

Family

ID=54250537

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2847286A Abandoned CA2847286A1 (fr)	2014-03-20	2014-03-20	Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete

Country Status (1)

Country	Link
CA (1)	CA2847286A1 (fr)

2014
- 2014-03-20 CA CA2847286A patent/CA2847286A1/fr not_active Abandoned

Publication	Publication Date	Title
CN110141663A (zh)	2019-08-20	通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途
EP3603660B1 (fr)	2025-01-15	Facteur 21 de croissance des fibroblastes humains mutants à action prolongée pour le traitement de la stéatohépatite non alcoolique
US20210338603A1 (en)	2021-11-04	Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes
US10959963B2 (en)	2021-03-30	Method for the treatment of fatty liver disease
US20130172424A1 (en)	2013-07-04	Methods and compositions for treating diabetes
DK2992888T3 (en)	2017-05-08	APPLICATION OF PENTACYCLIC TRITERPENOID SAPONE COMPOUND FROM SZECHUAN MELANDIUM ROOD TO PREPARATION OF HYPOGLYCEMIC MEDICINE
AU2014201695A1 (en)	2015-10-08	Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
US20150265644A1 (en)	2015-09-24	Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
CA2847250A1 (fr)	2015-09-20	Methodes et compositions therapeutiques pour le traitement du diabete
CA2847286A1 (fr)	2015-09-20	Methodes et compositions therapeutiques comportant des composes de diterpenoide pour le traitement du diabete
US20150265682A1 (en)	2015-09-24	Therapeutic methods and compositions for treating diabetes
KR20240032428A (ko)	2024-03-12	무화과 추출물을 포함하는 건선의 예방 및 치료용 조성물
EP3811948B1 (fr)	2024-09-11	Glycosides pour leur utilisation dans la prévention et le traitement des complications associées au diabète
CN103908567B (zh)	2017-04-05	一种用于治疗糖尿病痛性神经病变的复方制剂及其应用
AU2014201696A1 (en)	2015-10-08	Therapeutic methods and compositions for treating diabetes
Auberson et al.	1993	Lactic Acid‐Induced Plasma Protein Extravasation in Rat Airways by Stimulation of Sensory Nerves and NK1 Receptor Activation
US8765695B2 (en)	2014-07-01	Use of ginsenoside RG1, its metabolites ginsenoside RH1 and/or PPT
BR102014006730A2 (pt)	2015-12-01	métodos terapêuticos e composições para tratamento de diabetes
US10828286B2 (en)	2020-11-10	Niacin and berberine compositions and methods of use thereof
KR20150109774A (ko)	2015-10-02	당뇨병 치료를 위한 치료 방법 및 조성물
EP3804705B1 (fr)	2023-09-13	Composition pharmaceutique destinée à prévenir le diabète et utilisation correspondante
TWI248814B (en)	2006-02-11	Compositions comprising D-chiro inositol and lipid lowering compounds
RU2824275C1 (ru)	2024-08-07	Способ совместного применения интраназально вводимого инсулина и перорально вводимого метформина для восстановления метаболических и гормональных показателей при сахарном диабете 2 типа и метаболическом синдроме
US20150203430A1 (en)	2015-07-23	Compounds from antrodia camphorate and their use in treatment of diabetes mellitus
KR20220119065A (ko)	2022-08-26	불면증 치료를 위한 렘보렉산트의 용도

Legal Events

Date	Code	Title	Description
2017-05-02	FZDE	Dead	Effective date: 20170321